Oral News and Research

RSS

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The

25 Nov 2009

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety study in adults with acute myeloid leukemia (AML).

25 Nov 2009

Congress brings oral health into conversation to improve nation's overall health

The W.K. Kellogg Foundation commends Congress for its recognition of the urgent need to comprehensively and substantially strengthen oral health care for our most vulnerable children.

25 Nov 2009

US Patent & Trademark Office allows patent application for NOD technology

NOD Pharmaceuticals Inc. announced the US Patent & Trademark Office (PTO) has allowed the patent application for its nano-particle oral delivery or NOD technology.

25 Nov 2009

Incyte enters into collaboration and license agreement with Novartis

Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.

25 Nov 2009

Medical care in Germany for children with cancer is very good: IQWiG report

Internationally viewed, medical care in Germany for children with cancer is very good as far as survival is concerned. However, other aspects, such as quality of life, pain, and long-term consequences of the disease are still insufficiently investigated in studies. This is the conclusion of the Institute for Quality and Efficiency in Health Care (IQWiG) in its final report published on 16 October 2009.

25 Nov 2009

Shanghai Biolaxy receives IND approval for insulin formulation to treat diabetes

Shanghai Biolaxy announced the Chinese State Food & Drug Administration (SFDA) has approved the investigational new drug application (IND) for its oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes. This IND approval allows Biolaxy to initiate its first phase I clinical study.

24 Nov 2009

ADA and Temple University team up to improve oral health in underserved communities

The American Dental Association (ADA) has signed an agreement with Temple University to train new dental team members as part of a pilot program to improve the oral health in underserved communities.

24 Nov 2009

First-quarter fiscal 2010 results announced by China Aoxing Pharmaceutical

China Aoxing Pharmaceutical Company, Inc., a China-based pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products, today announced financial and operational results for the three month ended September 30, 2009, or the first quarter of fiscal year 2010.

24 Nov 2009

51st ASH meeting to feature 16 abstracts of MMRC

The Multiple Myeloma Research Consortium (MMRC) announced today that data from 13 of its clinical trials and three from the Multiple Myeloma Research Foundation (MMRF) Genomics Initiative, which analyzes tissue samples from the MMRC tissue bank, have been selected for oral or poster presentations at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH) to be held in New Orleans from December 5-8, 2009.

24 Nov 2009

Emergency dental solutions can ease pain and discomfort, according to survey

Nearly every household has some sort of a first aid kit filled with bandages, antiseptic, ointments and the like. But how many people plan ahead for dental emergencies?

24 Nov 2009

New technology developed to rapidly identify compounds for the treatment of heart failure

Research conducted by University of Minnesota scientists, in collaboration with Celladon Corporation, has led to the invention of technology to more rapidly identify compounds for the treatment of heart failure.

24 Nov 2009

Misconceptions about contraception contribute to lack of family-planning n Uganda

University of Alberta graduate student Jennifer Heys wants to make her message clear: there needs to be more education in Ugandan communities about contraception.

24 Nov 2009

Research suggests common oral bacterium may exacerbate autoimmune disease

Current research suggests that a common oral bacterium may exacerbate autoimmune disease. The related report by Nichols et al, "Unique Lipids from a Common Human Bacterium Represent a New Class of TLR2 Ligands Capable of Enhancing Autoimmunity," appears in the December 2009 issue of The American Journal of Pathology.

23 Nov 2009

New initiative launched to take care of patients with sickle cell disease

The Medical College of Georgia is leading an initiative that could result in a paradigm shift in the care of patients with sickle cell disease.

23 Nov 2009

Acucela to present data on its ACU-4429 visual cycle modulator for dry AMD

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that data for the company’s novel visual cycle modulator, ACU-4429, a potential oral treatment for dry age-related macular degeneration (dry AMD), will be featured at the 8th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) being held in Rome, Italy from December 3 to 6, 2009.

23 Nov 2009

Texas Court dismisses all claims against Merck in VIOXX-related lawsuit

Merck said today that Travis County, Texas District Court Judge Scott H. Jenkins granted Merck's motion for summary judgment, dismissing all claims in a VIOXX-related lawsuit filed on behalf of the State of Texas.

23 Nov 2009

New FluCide better than the older version

NanoViricides, Inc., announced today that Dr. Eugene Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent FluCide™ animal study on November 19th at the Influenza Congress USA 2009 in Washington, DC (www.terrapinn.com/usaflu). These data clearly established that the new version of FluCide™ is superior to the older version.

23 Nov 2009

STD infections continue to rise among young people

Sexually spread diseases continue to rise, with reported chlamydia cases setting yet another record in 2008, officials at the Centers for Disease Control recently reported. The CDC estimates that approximately 19 million new STD infections occur each year. Approximately half of them occur in young people between 15 to 24 years of age.

23 Nov 2009

New Drug Application for ticagrelor submitted to the FDA

AstraZeneca today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).

23 Nov 2009

Oral News and Research

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Congress brings oral health into conversation to improve nation's overall health

US Patent & Trademark Office allows patent application for NOD technology

Incyte enters into collaboration and license agreement with Novartis

Medical care in Germany for children with cancer is very good: IQWiG report

Shanghai Biolaxy receives IND approval for insulin formulation to treat diabetes

ADA and Temple University team up to improve oral health in underserved communities

First-quarter fiscal 2010 results announced by China Aoxing Pharmaceutical

51st ASH meeting to feature 16 abstracts of MMRC

Emergency dental solutions can ease pain and discomfort, according to survey

New technology developed to rapidly identify compounds for the treatment of heart failure

Misconceptions about contraception contribute to lack of family-planning n Uganda

Research suggests common oral bacterium may exacerbate autoimmune disease

New initiative launched to take care of patients with sickle cell disease

Acucela to present data on its ACU-4429 visual cycle modulator for dry AMD

Texas Court dismisses all claims against Merck in VIOXX-related lawsuit

New FluCide better than the older version

STD infections continue to rise among young people

New Drug Application for ticagrelor submitted to the FDA

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News